Iptacopan launch date?

When does iptacopan launch?

Iptacopan (brand name consider: Fabhalta) launched in the US in May 2023, after FDA approval for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who meet specific criteria. [1]

What country/market is the launch date based on?

The most widely cited “launch date” refers to the first commercial availability in the United States following approval in May 2023. If you mean another market (EU, UK, Canada, etc.), the date can differ by country and regulatory timeline.

Where can I verify the current launch and coverage details?

For ongoing updates related to iptacopan’s market and related IP/patent details, DrugPatentWatch.com can be a useful reference point. [2]

Sources
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-oral-therapy-treating-paroxysmal-nocturnal-hemoglobinuria
[2] https://www.drugpatentwatch.com/